Skip to Main Content
Our COVID-19 ResponseLearn More

Sawai Receives Approval for Tadalafil Tablets

Osaka, Japan – February 19, 2020 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) received approval by the Ministry of Health, Labour and Welfare (MHLW) for Tadalafil tablets (the branded product: Cialis®).

Tadalafil tablets are prescribed for the treatment of erectile dysfunction.

The products approved by MHLW on Feb. 19.

Product Name: TADALAFIL Tablets 10 mg CI [SAWAI], 20 mg CI [SAWAI]
Generic name: Tadalafil
Brand products: Cialis® Tablets 10 mg, 20 mg

The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.

PR / IR Group, Corporate Strategy Department, Sawai Pharmaceutical Co., Ltd.

E-mail: koho@sawai.co.jp